46 Applying Pharmacogenomics in Therapeutics5. Microarray uses the following biological principle to detect genomicvariations:a. Base-paring principle of nucleic acidsb. Gene transcriptionc. Protein modificationd. DNA replication6. Next-generation sequencing can be used for:a. Sequencing human genomesb. Detecting genetic variations in a populationc. Identifying disease-causing genesd. All of the aboveAnswer Key1. a2. d3. b4. d5. a6. dREFERENCESAlving, A. S., P. E. Carson, C. L. Flanagan, and C. E. Ickes. 1956. Enzymatic deficiency inprimaquine-sensitive erythrocytes. Science 124: 484–485.Augenlicht, L. H., and D. Kobrin. 1982. Cloning and screening of sequences expressed ina mouse colon tumor. Cancer Res 42: 1088–1093.Berglund, E. C., A. Kiialainen, and A. C. Syvanen. 2011. Next-generation sequencing technologiesand applications for human genetic history and forensics. Investig Genet 2: 23.Beutler, E. 2008. Glucose-6-phosphate dehydrogenase deficiency: A historical perspective.Blood 111: 16–24.Brenner, S., M. Johnson, J. Bridgham, G. Golda, D. H. Lloyd, et al. 2000. Gene expressionanalysis by massively parallel signature sequencing (MPSS) on microbead arrays.Nat Biotechnol 18: 630–634.Carlson, C. S., M. A. Eberle, L. Kruglyak, and D. A. Nickerson. 2004. Mapping complexdisease loci in whole-genome association studies. Nature 429: 446–452.Carlson, C. S., M. A. Eberle, M. J. Rieder, J. D. Smith, L. Kruglyak, D. A. Nickerson. 2003.Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genomeassociation studies in humans. Nat Genet 33: 518–521.Church, G. M. 2006. Genomes for all. Sci Am 294: 46–54.Cordero, P., and E. A. Ashley. 2012. Whole-genome sequencing in personalized therapeutics.Clin Pharmacol Ther 91: 1001–1009.Cordes, W. 1926. Experiences with plasmochin in malaria. In: Anonymous. 15th AnnualReport. Boston, MA: United Fruit Co, pp. 66–71.Crews, K. R., J. K. Hicks, C. H. Pui, M. V. Relling, and W. E. Evans. 2012. Pharmacogenomicsand individualized medicine: Translating science into practice. Clin Pharmacol Ther92: 467–475.Gabriel, S. B., S. F. Schaffner, H. Nguyen, J. M. Moore, J. Roy, et al. 2002. The structure ofhaplotype blocks in the human genome. Science 296: 2225–2229.
Principles of Pharmacogenetic Biotechnology and Testing in Clinical Practice47Gardner, K. R., F. X. Brennan, R. Scott, and J. Lombard. 2014. The potential utility of pharmacogenetictesting in psychiatry. Psychiatry J 2014: 730956.Gogol-Doring, A., and W. Chen. 2012. An overview of the analysis of next generationsequencing data. Methods Mol Biol 802: 249–257.Haga, S. B., and N. M. LaPointe. 2013. The potential impact of pharmacogenetic testing onmedication adherence. Pharmacogenomics J 13: 481–483.Harakalova, M., M. Mokry, B. Hrdlickova, I. Renkens, K. Duran, et al. 2011. Multiplexedarray-based and in-solution genomic enrichment for flexible and cost-effective targetednext-generation sequencing. Nat Protoc 6: 1870–1886.Heyries, K. A., C. Tropini, M. Vaninsberghe, C. Doolin, O. I. Petriv, et al. 2011. Megapixeldigital PCR. Nat Methods 8: 649–651.Hinds, D. A., L. L. Stuve, G. B. Nilsen, E. Halperin, E. Eskin, et al. 2005. Whole-genome patternsof common DNA variation in three human populations. Science 307: 1072–1079.Hindson, C. M., J. R. Chevillet, H. A. Briggs, E. N. Gallichotte, I. K. Ruf, et al. 2013. Absolutequantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10:1003–1005.Holland, P. M., R. D. Abramson, R. Watson, and D. H. Gelfand. 1991. Detection of specificpolymerase chain reaction product by utilizing the 5′–3′ exonuclease activity ofThermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88: 7276–7280.Iafrate, A. J., L. Feuk, M. N. Rivera, M. L. Listewnik, P. K. Donahoe, et al. 2004. Detectionof large-scale variation in the human genome. Nat Genet 36: 949–951.Ingelman-Sundberg, M. 2004. Pharmacogenetics of cytochrome P450 and its applicationsin drug therapy: The past, present and future. Trends Pharmacol Sci 25: 193–200.Johnson, J. A. 2003. Pharmacogenetics: Potential for individualized drug therapy throughgenetics. Trends Genet 19: 660–666.Jones, P. A., and S. B. Baylin. 2002. The fundamental role of epigenetic events in cancer.Nat Rev Genet 3: 415–428.Kalinina, O., I. Lebedeva, J. Brown, and J. Silver. 1997. Nanoliter scale PCR with TaqMandetection. Nucleic Acids Res 25: 1999–2004.Kalow, W. 1956. Familial incidence of low pseudocholinesterase level. Lancet 268: 576–577.Kalow, W. 1982. Ethnic differences in drug metabolism. Clin Pharmacokinet 7: 373–400.Kalow, W., B. K. Tang, D. Kadar, L. Endrenyi, and F. Y. Chan. 1979. A method for studyingdrug metabolism in populations: Racial differences in amobarbital metabolism. ClinPharmacol Ther 26: 766–776.Karch, S. B. 2007. Changing times: DNA resequencing and the “nearly normal autopsy.”J Forensic Leg Med 14: 389–397.Kidd, J. M., G. M. Cooper, W. F. Donahue, H. S. Hayden, N. Sampas, et al. 2008. Mappingand sequencing of structural variation from eight human genomes. Nature 453: 56–64.Kirchheiner, J., H. Schmidt, M. Tzvetkov, J. T. Keulen, J. Lotsch, et al. 2007. Pharmacokineticsof codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6duplication. Pharmacogenomics J 7: 257–265.Lander, E. S., L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, et al. 2001. Initial sequencingand analysis of the human genome. Nature 409: 860–921.Lashkari, D. A., J. L. DeRisi, J. H. McCusker, A. F. Namath, C. Gentile, et al. 1997. Yeastmicroarrays for genome wide parallel genetic and gene expression analysis. Proc NatlAcad Sci U S A 94: 13057–13062.Lee, S. Y., and H. L. McLeod. 2011. Pharmacogenetic tests in cancer chemotherapy: Whatphysicians should know for clinical application. J Pathol 223: 15–27.Levy, K. D., B. S. Decker, J. S. Carpenter, D. A. Flockhart, P. R. Dexter, et al. 2014.Prerequisites to implementing a pharmacogenomics program in a large health-caresystem. Clin Pharmacol Ther 96: 307–309.
Change language